
    
      Patients fulfill inclusion/exclusion criteria will be randomly assigned (in a 1:1 ratio)to
      receive intravenous cefoperazone/sulbactam or intravenous cefepime for 7~21days. Vitamin K1
      10mg will be administered to cefoperazone/sulbactam group every 24 hours.

      The assessment of clinical sign and symptoms of pneumonia and microbiological tests will be
      performed at early post-therapy visit and test-of-cure visit.
    
  